Targeting Spinal Long-Term Potentiation as a Basis for Analgesia Recent Developments [0.03%]
targeting spinal long-term potentiation作为镇痛的基础：最近的进展
Oliver Adolph,Karl Josef Föhr
Oliver Adolph
Recent investigations of pain mechanisms leading to the induction and maintenance of long-term potentiation (LTP) in the spinal cord have identified a huge number of molecular targets that might be appropriate for therapeutically interventi...
Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors [0.03%]
Exherin(ADH-1)治疗晚期实体瘤的I期临床试验
Nirit Yarom,David Stewart,Rajesh Malik et al.
Nirit Yarom et al.
ADH-1 (Exherin™) is a pentapeptide, which competitively inhibits N-cadherin, resulting in vascular disruptive effect of tumor vasculature in preclinical models. This study was designed to assess the toxicity of ADH-1 and to determine the m...
Clinical Trial
Current clinical pharmacology. 2013 Feb 1;8(1):81-8. DOI: 2013
Targeting spinal long-term potentiation as a basis for anlagesia: recent developments [0.03%]
targeting spinal long-term potentiation作为镇痛基础的最新进展
Oliver Adolph,Karl Josef Fohr
Oliver Adolph
Recent investigations of pain mechanisms leading to the induction and maintenance of long-term potentiation (LTP) in the spinal cord have identified a huge number of molecular targets that might be appropriate for therapeutically interventi...
Franco Polatti
Franco Polatti
As bacterial vaginosis (BV) is a potential cause of obstetric complications and gynecological disorders, there is substantial interest in establishing the most effective treatment. Standard treatment - metronidazole or clindamycin, by eithe...
Karel Allegaert
Karel Allegaert
Effective pain management remains an important indicator of the quality of care provided to neonates, not only from an ethical, but also from a clinical outcome perspective. Significant progresses in non-pharmacological therapies have been ...
Antibiotic resistance of bacterial strains isolated from patients with community-acquired urinary tract infections: an exploratory study in Palestine [0.03%]
来自社区获得性泌尿道感染患者的细菌菌株的抗生素抗药性的探索性研究：来自巴勒斯坦的研究
A S Abu-Taha,W M Sweileh
A S Abu-Taha
Background and objectives: No studies about resistance of bacteria isolated from patients with community-acquired urinary tract infections (CA-UTI) or local guidelines for antibiotic use in these infections have been publ...
Drug-induced anemia and other red cell disorders: a guide in the age of polypharmacy [0.03%]
药物引起的贫血和其他红细胞疾病：多药治疗时代的指南
Aryeh Shander,Mazyar Javidroozi,M E Ashton
Aryeh Shander
Several medications have been linked to red blood cell (RBC) disorders. The frequency of these side effects varies, depending on the condition, but they can be associated with significant morbidity and mortality. The problem is likely to ex...
Supplementation of glutamine and omega-3 polyunsaturated fatty acids as a novel therapeutic intervention targeting metabolic dysfunction and exercise intolerance in patients with heart failure [0.03%]
谷氨酰胺和ω-3多不饱和脂肪酸补充作为针对心力衰竭患者代谢功能障碍和运动不耐受的新疗法干预措施
Khurram Shahzad,Aalap Chokshi,P Christian Schulze
Khurram Shahzad
With its increasing prevalence throughout the world, heart failure continues to be associated with high morbidity and mortality. Patients with heart failure develop progressive metabolic abnormalities, inflammation, and atrophy in the myoca...
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer [0.03%]
晚期癌症患者使用伏立诺他与长春瑞滨联合治疗时意外出现伏立诺他高浓度现象
Peggy Gandia,Cecile Arellano,Quentin Chalret du Rieu et al.
Peggy Gandia et al.
Background: This study was a multi-centre, dose-escalation trial in patients with advanced cancers. Primary objective was to determine maximum tolerated dose (MTD) of vorinostat, a competitive inhibitor of histone deacety...
Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control [0.03%]
糖尿病外周神经病变治疗中的代谢纠正：症状控制之外的临床疗效改善
J R Miranda-Massari,M J Gonzalez,F J Jimenez et al.
J R Miranda-Massari et al.
Current Clinical Management Guidelines of Diabetic Peripheral Neuropathy (DPN) are based on adequate glucose control and symptomatic pain relief. However, meticulous glycemic control could delay the onset or slow the progression of diabetic...